Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

Item

http://www.wikidata.org/entity/Q35047860

Q35047860

about

"How many times must a man look up before he can really see the sky?" Rheumatic cardiovascular disease in the era of multimodality imaging.New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease Advanced tracers in PET imaging of cardiovascular disease SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease Clinical Utility and Future Applications of PET/CT and PET/CMR in Cardiology.Nuclear cardiology: 2014 innovations and developments Mitochondrial-Targeted Molecular Imaging in Cardiac Disease Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET Cardiac PET perfusion tracers: current status and future directions.CFR and FFR assessment with PET and CTA: strengths and limitations.Myocardial perfusion imaging with PET Start from Scratch: the Prospect of Nuclear Cardiology Synthesis and Evaluation of (18)F-labeled Pyridaben Analogues for Myocardial Perfusion Imaging in Mice, Rats and Chinese mini-swine.Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer.Pet Imaging and its Application in Cardiovascular Diseases.Diagnosing coronary artery disease with hybrid PET/CT: it takes two to tango.Coronary microvascular dysfunction: mechanisms and functional assessment.Radionuclide myocardial perfusion imaging for the evaluation of patients with known or suspected coronary artery disease in the era of multimodality cardiovascular imaging.Cardiac PET for translational imaging.Stress echocardiography: what is new and how does it compare with myocardial perfusion imaging and other modalities?Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography.Assessing time-of-flight signal-to-noise ratio gains within the myocardium and subsequent reductions in administered activity in cardiac PET studies.PET/MR: Yet another Tesla?Recent Advances in Nuclear Cardiology Absolute quantification of myocardial blood flow.Impact of motion and partial volume effects correction on PET myocardial perfusion imaging using simultaneous PET-MR.PET imaging in heart failure: the role of new tracers.The role of PET quantification in cardiovascular imaging.Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?(18)F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines.Value of Hybrid Imaging with PET/CT to Guide Percutaneous Revascularization of Chronic Total Coronary Occlusion Association of coronary plaque burden with fractional flow reserve: should we keep attempting to derive physiology from anatomy?PET should replace SPECT in cardiac imaging for diagnosis and risk assessment of patients with known or suspected CAD: Pro.Beyond ultrasound: advances in multimodality cardiac imaging.Role of Cardiac PET in Clinical Practice.Radiopharmaceutical tracers for cardiac imaging.New chemical and radiochemical routes to [18F]Rho6G-DEG-F, a delocalized lipophilic cation for myocardial perfusion imaging with PET.Advances in imaging instrumentation for nuclear cardiology.Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging.

P2860

Q26785666-813638D1-087D-44A8-AFE6-9F9FBBC80F49 Q27011866-9993631A-72AA-4789-8700-E552C5DD5D51 Q27023690-7026FC64-3ED0-4C0B-BAB4-17E7687755B0 Q28066121-85131604-283F-4589-A4CC-A329DAA793BD Q28073135-E3976E7E-7480-489C-AE43-764BB3FA8F8D Q28081835-6CED6ABA-4083-47DB-BD91-30275B6BF959 Q33790688-533AFA9C-2856-444C-9CB2-F7BE401F504D Q35044167-2A0FF880-B1ED-48BC-B176-7A034EF995A9 Q35097258-8938E041-2AE7-4706-A561-F902024048C5 Q36081581-30246CB8-423C-4B3C-8D89-ABAC28853401 Q36834147-32032F63-E686-4B5D-BC7D-05F2875BC8DC Q36910290-A3C26C09-4C51-4FFF-9BE2-6D635680607E Q37267327-02520C09-926D-4E25-88C7-F92956D3953E Q37287803-5E6FE1BC-63F1-4392-84B8-941CEB8CCD0B Q37743798-E3B81158-209E-401F-B294-1A00EF8E24FC Q38120658-3515E0EB-7D0A-4A1F-B22D-34FAA0A03CEA Q38259726-41F0E27F-A4A5-403D-AC2E-C05E688BD9C9 Q38377656-B8D8BF94-8597-46D0-A1DD-BFCDE425FEF3 Q38430736-80F3F684-18F6-46D3-89C6-E317A5066105 Q38441632-7685C51F-73FE-4B75-9707-347C13031A22 Q38670162-4DB1B81F-3F93-4599-894D-158B456DE9DC Q38737734-2A3AA308-A03D-44C9-B495-45D3F84B253E Q38790061-C0512956-4D7F-47DE-8AAC-9BFD886A3A20 Q38818563-47C9D8EA-25D0-48A2-8241-A73B9BB40A0F Q38829878-53AA9736-E8CC-4090-BB87-7335E5AE2A06 Q38905038-1138E400-56D8-4513-A960-A694E9CD6480 Q39083985-D5B6AA7F-6150-4376-A25C-8C61C2B6E5E2 Q39285234-D6261822-01E1-47DB-B218-7D9B537EEBE4 Q40655323-CA26EB63-06FC-470C-84A5-27157CCE043F Q41871815-428A7C52-020C-4D69-A89C-6C79059B26E9 Q42135474-28DCFB4A-4C9D-4CE8-8217-71243E593074 Q42535948-CB484AE8-9230-422B-B209-16F5024D1BF4 Q43147789-822DAB5F-575F-412A-A2A1-C4F3E15E6112 Q43658240-201941E6-AB1D-4113-ACD8-70FB1E871326 Q46195604-7B3ED077-B6E0-42D1-B884-35BA9CB4889A Q47628378-AA8BABC7-4493-4F55-99C8-1B7B10E9AD51 Q49352380-8DF637EE-9F1C-47EC-B2E4-208F336BE7A9 Q49585267-E9F8E3FE-AADE-4FF3-997F-DBDE391C342A Q50526937-5EE2E423-BADB-4213-8611-7401D9C4E3B6 Q52936656-2CDD5818-DFE2-4E6E-B182-2BC10BBC1FEF

P2860

Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

Item

http://www.wikidata.org/entity/Q35047860

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase II safety and clinical c ...... positron emission tomography.

@en

type

Item

label

Phase II safety and clinical c ...... positron emission tomography.

@en

prefLabel

Phase II safety and clinical c ...... positron emission tomography.

@en

P1476

Phase II safety and clinical c ...... positron emission tomography.

@en

P2093

B K Tamarappoo

http://www.w3.org/2001/XMLSchema#string

C Michael Gibson

http://www.w3.org/2001/XMLSchema#string

Dana Washburn

http://www.w3.org/2001/XMLSchema#string

Daniel S Berman

http://www.w3.org/2001/XMLSchema#string

Gajanan Bhat

http://www.w3.org/2001/XMLSchema#string

James E Udelson

http://www.w3.org/2001/XMLSchema#string

Jamshid Maddahi

http://www.w3.org/2001/XMLSchema#string

Joel Lazewatsky

http://www.w3.org/2001/XMLSchema#string

Johannes Czernin

http://www.w3.org/2001/XMLSchema#string

Marybeth Devine

http://www.w3.org/2001/XMLSchema#string

P2860

ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Comparison between 201Tl and 99mTc sestamibi uptake during adenosine-induced vasodilation as a function of coronary stenosis severity.

Myocardial 99mTc-tetrofosmin uptake during adenosine-induced vasodilatation with either a critical or mild coronary stenosis: comparison with 201Tl and regional myocardial blood flow.

Properties of an ideal PET perfusion tracer: new PET tracer cases and data.

Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT.

Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging.

Comparison of clinical tools for measurements of regional stress and rest myocardial blood flow assessed with 13N-ammonia PET/CT.

Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.

Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model.

P304

469-477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2012.11.022

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233982839

http://www.w3.org/2001/XMLSchema#string

P698

23265345

http://www.w3.org/2001/XMLSchema#string

P932

4316725

http://www.w3.org/2001/XMLSchema#string

Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

about

P2860

P2860

Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932